4.2 Article

Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: A prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology

Rate this paper

The primary rating indicates the level of overall quality for the paper. Secondary ratings independently reflect strengths or weaknesses of the paper.

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now